Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ramelteon.

Adam McGechan1, Keri Wellington

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|December 8, 2005
PubMed
Summary
This summary is machine-generated.

Ramelteon effectively treats insomnia by targeting melatonin receptors, improving sleep onset and duration. This selective agonist demonstrates a favorable safety profile with no observed abuse potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Sleep Medicine
  • Neuroscience

Background:

  • Insomnia is a prevalent sleep disorder affecting sleep onset and maintenance.
  • Melatonin MT1/MT2 receptors play a crucial role in regulating circadian rhythms.
  • Selective agonists offer potential therapeutic advantages with improved safety profiles.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ramelteon for insomnia treatment.
  • To assess ramelteon's effects on sleep latency, total sleep time, and sleep efficiency.
  • To determine the safety profile and potential for abuse or dependence of ramelteon.

Main Methods:

  • Ramelteon (8mg) was administered to patients with chronic insomnia in three clinical trials.
  • A first-night-effect model was used to assess ramelteon's efficacy in transient insomnia.

Related Experiment Videos

  • Adverse events and potential for abuse/dependence were monitored.

    • Main Results:

    • Ramelteon (8mg) significantly reduced sleep latency in chronic and transient insomnia models.
    • The drug generally increased total sleep time and sleep efficiency.
    • Ramelteon was well-tolerated, with mild-to-moderate adverse events like somnolence, fatigue, and dizziness; no significant abuse potential was observed.

    Conclusions:

    • Ramelteon is an effective treatment for insomnia, particularly sleep onset difficulties.
    • Its selective action on melatonin receptors contributes to a favorable safety and tolerability profile.
    • Ramelteon presents a low risk for abuse or dependence, making it a viable therapeutic option.